China healthcare Report Interpretation

Overview

This industry earnings review combines 1H26 results for major China healthcare companies with takeaways from Nomura CIF 2026 meetings. Nomura sees resilient reported performance and a generally upbeat outlook for 2H26E, led by innovative-drug commercialization and CRDMO demand.

Core views

Nomura reports that China healthcare rebounded from a trough in mid-June as sentiment and fund inflows recovered following solid results from leading companies. Over the preceding three months, CSI 300 Healthcare rose 17% versus a 6% decline for CSI 300, while MSCI China Healthcare gained 29% versus a 2% decline for MSCI China. The institution had previewed 18 major companies' 2Q/1H26 results in late July and concludes that its forecasts proved conservative: 10 companies beat its revenue estimates and 11 beat its earnings forecasts. This resilience came despite foreign-exchange effects, policy headwinds and weak demand. Nomura attributes the results to several operating drivers. CRDMOs benefited from rising global competitiveness and drug R&D and manufacturing demand; pharma and biotech companies saw continued sales ramp-ups for innovative drugs and collaboration revenue; medical-device and healthcare-service companies advanced overseas penetration or exploration; and pharmacies improved efficiency. In its broader screen of 145 A-share healthcare companies with market capitalization above USD1.5bn and 104 Hong Kong-listed companies above USD0.5bn, biotech and CRO companies outperformed other segments on median sales and earnings growth. Nomura argues that rising innovative-drug volumes can generate economies of scale, narrow operating losses or produce positive earnings, while collaboration income provides an additional support. It therefore sees innovative-drug development and commercialization as the sector's growth engine. At CIF 2026, five leading China CRDMOs—Wuxi AppTec, Wuxi XDC, Wuxi Bio, Asymchem and Pharmaron—reported strong 1H26 backlog growth, chiefly from manufacturing orders. To meet those orders, most raised FY26E/27E capex plans. Management remained positive on 2H26E and FY27E gross-margin prospects despite potential foreign-exchange pressure and depreciation from new facilities, citing scale economies and further efficiency improvement. The report therefore links visible order backlogs and expanding capacity to continued sector activity, while recognizing that margin delivery must offset those cost pressures. Participating pharma and biotech companies were also constructive on commercial sales ramp-ups, clinical readouts and medium-term international development. Examples include SBP and Innovent on commercial progress, Kelun Bio and Leads Bio on clinical catalysts, and companies discussing mRNA cancer vaccines, siRNA for chronic diseases and oral GLP-1 drugs. Henlius targets meaningful US biosimilar sales, while Innovent aims for at least five late-stage pipelines globally around 2030E. Domestic-oriented companies cited improving conditions as well: Hygeia reported faster medical-insurance payments and more inbound medical tourists at its Chongqing hospital; Yifeng saw continued same-store-sales growth in 3Q26; and iRay Tech expects its new PCB business to support growth as conventional medical-equipment growth flattens. Expert sessions added context on emerging healthcare themes. An AIDD expert argued that agility and collaboration between AI scientists and laboratory researchers matter more than data scale, but noted that AI currently only modestly improves the probability of success at each stage of a 30-40-step drug-development process. The expert suggested judging an AI biotech platform by the number of platform collaborations rather than isolated asset out-licensing deals. A GLP-1 expert estimated China's market at CNY40bn despite low global pricing, but expected the attractive market ultimately to accommodate only five to six players because medical-insurance coverage and brand awareness matter; muscle-preservation niches were identified as worth following, while generics were viewed less favorably. A peptide-CDMO expert said GLP-1 API cost is about 1% of the Chinese end-user price, with CDMO gross margins above 60% and roughly one-and-a-half months needed for a manufacturing batch. A BCI expert noted local-government support for clinical resources and insurance coverage, China's gap in surgical robots used for implantation, and a more favorable commercial outlook for consumer-grade than medical BCI products.

Analysis framework

Nomura first compares reported 1H26 revenue and earnings with its forecasts for 18 major covered companies, then screens median growth across A-share and Hong Kong-listed healthcare segments. It supplements this financial review with management discussions from around 30 meetings with about 20 corporates and four expert sessions at CIF 2026, linking results and outlooks to demand, backlog, commercialization, capacity, margin and technology-development drivers.

Methodology notes

• Industry AnalysisVolume-price decomposition

  Segment-level revenue and earnings-growth comparison

  The report compares median sales and profit growth across healthcare subsectors to identify biotech and CRO as relative leaders.

• Industry AnalysisSupply-demand framework

  CRDMO backlog, capacity expansion and margin outlook analysis

  Nomura uses order backlogs, planned capex, scale economies and cost pressures to explain the expected path for CRDMO growth and margins.

• Other

  Results versus Nomura forecast comparison

  The report measures whether reported revenue and earnings were above or below Nomura's prior estimates to assess the strength of 1H26 delivery.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Wuxi AppTec (2359 HK / 603259 CH)

  Covered CRDMO cited as a leading company with solid results and strong manufacturing-order backlog growth.

  Strengths

  Global competitiveness and manufacturing demand.

  Weaknesses

  Foreign-exchange effects and depreciation from new facilities may pressure margins.

  Comparison

  Part of the leading CRDMO group reporting strong backlog growth.

  Risks

  Gross-margin outlook depends on scale economies and efficiency offsetting cost pressures.

• SBP (1177 HK)

  Covered pharma company cited for commercial sales ramp-up.

  Strengths

  1H26 revenue of 19,444 versus 17,575 in 1H25 and net profit of 3,435 versus 3,389.

  Weaknesses

  Revenue was 5.1% above Nomura's forecast while earnings were 109.6% above it, indicating uneven forecast delivery across metrics.

  Comparison

  Part of the pharma cohort benefiting from innovative-drug commercialization.

• Innovent (1801 HK)

  Covered biotech company cited for commercial sales ramp-up and international pipeline ambitions.

  Strengths

  1H26 revenue rose 47.2% and net profit rose 50.2%; it aims for at least five late-stage global pipelines around 2030E.

  Weaknesses

  1H26 revenue was 5.3% below Nomura's forecast.

  Comparison

  A biotech leader in the report's stronger-performing segment.

  Risks

  Execution of global pipeline development and commercialization.

• Hygeia (6078 HK)

  Covered hospital operator cited as seeing an improved domestic operating environment.

  Strengths

  Faster medical-insurance payments and increased inbound medical tourists at Chongqing Hygeia hospital.

  Comparison

  Represents domestic-business-oriented healthcare companies benefiting from operating improvements.

Key data

• Companies exceeding revenue estimates10 of 18Major Chinese healthcare companies reviewed for 2Q/1H26
• Companies exceeding earnings forecasts11 of 18Major Chinese healthcare companies reviewed for 2Q/1H26
• CSI 300 Healthcare performance+17%Over the past three months, versus CSI 300 at -6%
• MSCI China Healthcare performance+29%Over the past three months, versus MSCI China at -2%
• A-share healthcare screening universe145 companiesMainland-listed companies with market capitalization above USD1.5bn as of 4 September
• Hong Kong healthcare screening universe104 companiesHong Kong-listed companies with market capitalization above USD0.5bn as of 4 September
• China GLP-1 market estimateCNY40bnExpert's estimate of the commercial opportunity
• Expected number of viable GLP-1 players5-6Expert expectation based on insurance coverage and brand awareness

Impact & implications

Nomura's findings support a constructive sector view for 2H26E: innovative-drug commercialization, global CRDMO demand, collaboration revenue, operating efficiency and selected domestic-demand improvements are presented as the principal growth supports. The report also indicates that margin delivery, clinical progress, overseas expansion and competitive concentration will differentiate outcomes across subsectors.

Risks

• Foreign-exchange effects and incremental depreciation from new facilities could pressure CRDMO gross margins.
• Policy headwinds and weak demand remained unfavorable external factors during 1H26.
• AI currently only modestly improves success odds at individual drug-R&D steps, leaving a complex 30-40-step process difficult to transform.
• The GLP-1 market may be limited to five to six meaningful players, making brand awareness and insurance coverage important competitive constraints.
• China remains behind overseas leaders in surgical robots used to implant BCI products.

What to watch

• CRDMO manufacturing-order backlog conversion, FY26E/27E capex execution and gross-margin trends in 2H26E and FY27E.
• Commercial sales ramp-ups for innovative drugs, collaboration revenue and upcoming clinical readouts.
• Progress in overseas commercialization and global pipeline development by Chinese biotech companies.
• GLP-1 market concentration, insurance coverage, brand development and emerging muscle-preservation niches.
• Operational indicators at domestic healthcare businesses, including insurance-payment timing, same-store sales and new-business growth.